BEHNKE v. CVS CAREMARK CORPORATION et al

  1. September 16, 2025

    CVS Caremark Takes $290M Overbilling Judgment To 3rd Circ.

    CVS's pharmacy benefits manager will appeal a judgment against the company that was recently increased from $95 million to $290 million in a suit alleging it overbilled Medicare Part D-sponsored drugs, according to a notice of appeal filed in Pennsylvania federal court.

  2. August 20, 2025

    CVS PBM Overbilling Judgment Trebled To $290M

    A Pennsylvania federal judge has increased threefold a judgment against CVS Caremark from $95 million to $290 million for overbilling Medicare Part D-sponsored drugs.

  3. June 25, 2025

    CVS PBM Hit With $95M Judgment For Overbilling Medicare

    A Pennsylvania federal judge on Wednesday ruled that CVS's pharmacy benefits manager owes the government $95 million for overbilling Medicare Part D-sponsored drugs, leaving the door open for the amount to be tripled later.

  4. March 10, 2025

    CVS PBM Caused Up To $330M In Part D Damages, Judge Told

    A CVS-owned pharmacy benefits manager caused anywhere from $240 million to $330 million in damages by overbilling the government for Medicare Part D sponsored drugs, counsel for a whistleblower told a Pennsylvania federal judge at the beginning of a False Claims Act bench trial on Monday.

  5. July 31, 2024

    CVS Appeal Blocked In Whistleblower Suit Over Drug Prices

    A Pennsylvania federal judge has barred CVS Health Co. from making an interlocutory appeal over his interpretation of regulations in a whistleblower's lawsuit claiming the company's prescription entities falsely reported drug prices to the government. The judge recommended that a trial date be set in the decade-long litigation instead.

  6. April 23, 2020

    CVS Units Get Whistleblower's Rx FCA Suit Trimmed, For Now

    A Pennsylvania federal judge on Thursday trimmed claims in a whistleblower's False Claims Act suit alleging two CVS Health Co. prescription entities ran a scheme to defraud the government by falsely reporting drug prices subsidized under Medicare Part D, but will let the relator rework her claims.